Hikma Pharmaceuticals (HIK N) Stock Overview

Develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. More details

HIK N fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	4/6
Financial Health	4/6
Dividends	5/6

Rewards

Trading at 51.3% below our estimate of its fair value

Earnings are forecast to grow 13.24% per year

Earnings grew by 30.2% over the past year

Pays a reliable dividend of 4.08%

Risk Analysis

Shares are highly illiquid

Has a high level of debt

HIK N Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Hikma Pharmaceuticals PLC Competitors

Price History & Performance

Summary of share price highs, lows and changes for Hikma Pharmaceuticals
Historical stock prices
Current Share Price	UK£432.63
52 Week High	UK£432.63
52 Week Low	UK£432.63
Beta	0.71
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	5.49%

Recent updates

Shareholder Returns

	HIK N	MX Pharmaceuticals	MX Market
7D	0%	-0.8%	-1.5%
1Y	n/a	3.7%	17.8%

Return vs Industry: Insufficient data to determine how HIK N performed against the MX Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how HIK N performed against the MX Market.

Price Volatility

Is HIK N's price volatile compared to industry and market?
HIK N volatility
HIK N Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.3%
Market Average Movement	3.8%
10% most volatile stocks in MX Market	6.4%
10% least volatile stocks in MX Market	2.2%

Stable Share Price: HIK N's share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine HIK N's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1978	9,500	Riad Mishlawi	www.hikma.com

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals.

Hikma Pharmaceuticals PLC Fundamentals Summary

How do Hikma Pharmaceuticals's earnings and revenue compare to its market cap?
HIK N fundamental statistics
Market cap	Mex$83.80b
Earnings (TTM)	Mex$6.81b
Revenue (TTM)	Mex$59.06b

12.3x

P/E Ratio

1.4x

P/S Ratio

Is HIK N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HIK N income statement (TTM)
Revenue	US$3.22b
Cost of Revenue	US$1.83b
Gross Profit	US$1.38b
Other Expenses	US$1.01b
Earnings	US$371.00m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	1.68
Gross Margin	43.03%
Net Profit Margin	11.54%
Debt/Equity Ratio	59.0%

How did HIK N perform over the long term?

See historical performance and comparison

Dividends

4.1%

Current Dividend Yield

50%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/11/20 20:57
End of Day Share Price	2025/09/05 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hikma Pharmaceuticals PLC is covered by 28 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Simon Mather	Barclays
Sidhartha Modi	Barclays
Emily Field	Barclays

Hikma Pharmaceuticals PLCBMV:HIK N Stock Report